Relacorilant

Generic Name: Relacorilant

Brand Names: -

Drug Type: Small Molecule

Chemical Formula: C_₂₇H_₂₂F_₄N_₆O_₃S

CAS Number: 1496510-51-0

Unique Ingredient Identifier: 2158753C7E

Background: Relacorilant is under investigation in clinical trial NCT02804750 (Study to Evaluate CORT125134 in Patients With Cushing's Syndrome).

Associated Conditions: -

Associated Therapies: -

Clinical Trials

A Study to Evaluate the Pharmacokinetics of the CORT125134 Phase 2 Formulation in Healthy Male Subjects

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: CORT125134

First Posted Date: 2023-10-23

Last Posted Date: 2023-10-23

Lead Sponsor: Corcept Therapeutics

Target Recruit Count: 8

Registration Number: NCT06094712

Locations: 🇺🇸
Jasper Clinic, Kalamazoo, Michigan, United States

A Study to Evaluate the Effects of Hepatic Impairment on the Pharmacokinetics of Relacorilant

Phase 1

Completed

Conditions: Hepatic Impairment

Interventions: Drug: Relacorilant

First Posted Date: 2023-10-23

Last Posted Date: 2023-10-23

Lead Sponsor: Corcept Therapeutics

Target Recruit Count: 30

Registration Number: NCT06094725

Locations: 🇺🇸
Clinical Pharmacology of Miami, LLC, Miami, Florida, United States
🇺🇸
Orlando Clinical Research Center, Orlando, Florida, United States

A Study of Enzalutamide Plus the Glucocorticoid Receptor Antagonist Relacorilant Versus Placebo for Patients With High-risk Localized Prostate Cancer

Phase 2

Recruiting

Conditions: Prostate Adenocarcinoma
Prostate Cancer

Interventions: Drug: Relacorilant
Other: Placebo (Sugar Pill)
Drug: Enzalutamide
Other: Androgen Deprivation Therapy
Procedure: Radical Prostatectomy

First Posted Date: 2023-02-13

Last Posted Date: 2024-08-14

Lead Sponsor: University of Chicago

Target Recruit Count: 90

Registration Number: NCT05726292

Locations: 🇺🇸
University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States
🇺🇸
University of Texas Southwestern Medical Center, Dallas, Texas, United States

Effect of Relacorilant on the Pharmacokinetics of the Sensitive P-glycoprotein Substrate Dabigatran Etexilate in Healthy Participants

Phase 1

Completed

Conditions: Cushing Syndrome
Neoplasms

Interventions: Drug: Dabigatran Etexilate
Drug: Relacorilant

First Posted Date: 2022-04-27

Last Posted Date: 2023-02-09

Lead Sponsor: Corcept Therapeutics

Target Recruit Count: 30

Registration Number: NCT05347979

Locations: 🇺🇸
Site 01, Miami, Florida, United States

T/QT Study to Investigate the Effect of Relacorilant on Cardiac Repolarization in Healthy Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Relacorilant
Drug: Placebo to relacorilant
Drug: Moxifloxacin

First Posted Date: 2021-03-12

Last Posted Date: 2021-09-14

Lead Sponsor: Corcept Therapeutics

Target Recruit Count: 36

Registration Number: NCT04795479

Locations: 🇺🇸
Single Site, Springfield, Missouri, United States

Study of Relacorilant in Combination With Pembrolizumab for Patients With Adrenocortical Carcinoma Which Produces Too Much Stress Hormone (Cortisol)

Phase 1

Completed

Conditions: Adrenocortical Carcinoma

Interventions: Drug: Relacorilant
Drug: Pembrolizumab

First Posted Date: 2020-05-04

Last Posted Date: 2024-02-23

Lead Sponsor: Corcept Therapeutics

Target Recruit Count: 15

Registration Number: NCT04373265

Locations: 🇺🇸
Site #183, The University of Texas M.D. Anderson Cancer Center, Houston, Texas, United States
🇺🇸
Site #030 Mayo Clinic, Rochester, Minnesota, United States
🇺🇸
Site #150, Stanford Cancer Center, Stanford, California, United States

and more 3 locations

Efficacy and Safety of Relacorilant in Patients With Cortisol-Secreting Adrenal Adenomas

Phase 3

Completed

Conditions: Hypercortisolism

Interventions: Drug: relacorilant
Other: Placebo

First Posted Date: 2020-03-16

Last Posted Date: 2024-11-19

Lead Sponsor: Corcept Therapeutics

Target Recruit Count: 137

Registration Number: NCT04308590

Locations: 🇺🇸
Site 21, Columbus, Ohio, United States
🇺🇸
Site 27, Birmingham, Alabama, United States
🇺🇸
Site 17, Stanford, California, United States

and more 42 locations

A Study of the Efficacy and Safety of Relacorilant in Patients With Endogenous Cushing Syndrome

Phase 3

Completed

Conditions: Cushing Syndrome

Interventions: Drug: Relacorilant
Other: Placebo

First Posted Date: 2018-10-05

Last Posted Date: 2024-08-29

Lead Sponsor: Corcept Therapeutics

Target Recruit Count: 152

Registration Number: NCT03697109

Locations: 🇺🇸
Site 41, Chicago, Illinois, United States
🇺🇸
Site 46, Boston, Massachusetts, United States
🇺🇸
Site 7, Indianapolis, Indiana, United States

and more 60 locations

Study of Drug 1 (Enzalutamide) Plus Drug 2 (Relacorilant) for Patients With Prostate Cancer

Phase 1

Active, not recruiting

Conditions: Prostate Cancer

Interventions: Drug: Enzalutamide
Drug: Relacorilant

First Posted Date: 2018-09-18

Last Posted Date: 2024-07-31

Lead Sponsor: University of Chicago

Target Recruit Count: 35

Registration Number: NCT03674814

Locations: 🇺🇸
University Of Chicago Medicine Comprehensive Cancer Center, Chicago, Illinois, United States

Extension Study to Evaluate the Safety of Long-Term Use of Relacorilant in Patients With Cushing Syndrome

Phase 2

Active, not recruiting

Conditions: Cushing Syndrome

Interventions: Drug: relacorilant

First Posted Date: 2018-07-27

Last Posted Date: 2024-12-09

Lead Sponsor: Corcept Therapeutics

Target Recruit Count: 125

Registration Number: NCT03604198

Locations: 🇺🇸
Site 3, Saint Louis, Missouri, United States
🇺🇸
Site 55, Reno, Nevada, United States
🇺🇸
Site 2, Pittsburgh, Pennsylvania, United States

and more 49 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy